The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2008, 181, 3558-3566
Copyright © 2008 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uozumi, N.
Right arrow Articles by Shimizu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uozumi, N.
Right arrow Articles by Shimizu, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Sepsis

Modulation of Lipid and Protein Mediators of Inflammation by Cytosolic Phospholipase A2{alpha} during Experimental Sepsis1

Naonori Uozumi2, Yoshihiro Kita and Takao Shimizu3

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Tokyo, Japan

Cytosolic phospholipase A2{alpha} (cPLA2{alpha}) is one of the key enzymes in lipid mediator generation. It preferentially hydrolyzes arachidonoyl-phospholipid in response to cellular stimuli, liberating arachidonic acid, the shared precursor of PGs and leukotrienes. Mice with disruption of the cPLA2{alpha} gene exhibit a more than 80% decrease in the generation of these lipid mediators, leading to dramatic phenotypes in various models of inflammatory and allergic disease. In this study, we use the cecal ligation and puncture model of sepsis along with multiplex quantitation systems to explore interactions between eicosanoids and protein mediators. cPLA2{alpha}-deficient mice exhibited significantly less weight loss accompanied by decreased generation of PGs, leukotriene B4, IL-6, and CCL2. Despite these differences, genetic ablation of cPLA2{alpha} did not provide any survival advantage. Unexpectedly, abundant production of 12-hydroxy-eicosatetraenoic acid, another arachidonic acid-derived lipid mediator, was found to be unaffected by disruption of the cPLA2{alpha} gene. Eicosanoid production preceded the production of cytokines. Eicosanoid modulation of IL-6 and CCL2 expression was suggested by scattergram analyses. These results provide in vivo evidence for the rapid generation of eicosanoids, regulatory role(s) for cPLA2{alpha}-derived lipid mediators on protein mediator production, and the existence of a robust cPLA2{alpha}-independent pathway(s) of eicosanoid generation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T.S. and N.U.), and a grant from Ono Medical Research Foundation (to N.U.).

2 Current address: Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229.

3 Address correspondence and reprint requests to Dr. Takao Shimizu, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail address: tshimizu{at}m.u-tokyo.ac.jp

4 Abbreviations used in this paper: CLP, cecal ligation and puncture; COX, cyclooxygenase; cPGI2, carbaprostacyclin; cPLA2, cytosolic phospholipase A2; HETE, hydroxy-eicosatetraenoic acid; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LO, lipoxygenase; LT, leukotriene; PGI2, prostacyclin; PLA2, phospholipase A2; sPLA2, secretory PLA2; D(–)-PBS, Dulbecco’s PBS without calcium chloride and magnesium chloride; PAF, platelet-activating factor; Tx, thromboxane.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.